LOS ANGELES—An international study co-led by UCLA found that an investigational targeted therapy significantly extended survival for pancreatic cancer patients, researchers said on May 31.
The study found that patients who received the drug daraxonrasib lived a median of 13.2 months compared with 6.7 months for those who received investigator’s choice chemotherapy.
That represented a 60 percent reduction in risk of death for patients with previously treated metastatic pancreatic cancer, compared to standard chemotherapy.
The study was funded by Revolution Medicines.
The findings suggest a potential treatment option for patients with metastatic pancreatic cancer, a disease that remains among the most lethal cancers and has limited effective therapies….